Meningitis outbreak: New England Compounding Pharmacy files bankruptcy

Vials of the injectable steroid product made by

Vials of the injectable steroid product made by New England Compounding Center implicated in a fungal meningitis outbreak that were being shipped to the CDC from Minneapolis. Massachusetts shut down another compounding pharmacy over sterility concerns after a surprise inspection prompted by the nationwide meningitis outbreak linked to a different company, state officials have said. (Oct. 29, 2012) Photo Credit: AP

advertisement | advertise on newsday

New England Compounding Pharmacy Inc., the Mass. pharmaceutical company blamed for a nationwide meningitis outbreak, filed for bankruptcy protection to deal with lawsuits filed against it.

More than 30 people died and 490 were injured after the company shipped fungus-tainted drugs to customers throughout the U.S., according to the Centers for Disease Control and Prevention. The company plans to establish a fund under Chapter 11 of the U.S. Bankruptcy Code to compensate individuals and families affected by the outbreak.

advertisement | advertise on newsday

The Framingham-based company listed both assets and debt of $1 million to $10 million in Chapter 11 documents filed yesterday in U.S. Bankruptcy Court in Boston.

New England Compounding's "goal is to provide a greater, quicker, fairer payout to its creditors than they could achieve through piecemeal litigation," the company said Friday in a statement.

Under bankruptcy law, all litigation against a company or individual who seeks protection is put on hold while the case is pending. A judge can grant a request to allow the claims to proceed outside bankruptcy court in some instances.

The case is In re New England Compounding Pharmacy Inc., 12-19882, U.S. Bankruptcy Court, District of Massachusetts (Boston).

Comments

Newsday.com now uses Facebook for our comment boards. Please read our guidelines and connect your Facebook account to comment.

You also may be interested in: